Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

被引：28

作者：

De Stefano, Nicola ^{[1
]}

Curtin, Francois ^{[2
,7
]}

Stubinski, Bettina ^{[2
,7
]}

Blevins, Gregg ^{[3
]}

Drulovic, Jelena ^{[4
]}

Issard, Delphine ^{[2
,7
]}

Shotekov, Penko ^{[5
]}

Gasperini, Claudio ^{[6
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy

[2] Merck Serono SA, Geneva, Switzerland

[3] Univ Alberta, Div Neurol, Edmonton, AB, Canada

[4] Univ Belgrade, Inst Neurol, Clin Ctr Serbia, Belgrade, Serbia

[5] UMBAL Alexandovska, Neurol Clin, Sofia, Bulgaria

[6] San Camillo Forlanini Hosp, Rome, Italy

[7] Merck KGaA, Darmstadt, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2010年 / 16卷 / 07期

关键词：

efficacy; interferon beta-1a; magnetic resonance imaging; randomized controlled trial; relapsing-remitting multiple sclerosis;

D O I：

10.1177/1352458510362442

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

w This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta 1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n=180) were randomized (2:1) to IFN-beta 1a or placebo for 16 weeks; all patients then received IFN-beta 1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta 1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-beta 1a by week 4 ( post hoc analysis; p=0.015). The new formulation of sc IFN-beta 1a has rapid beneficial effects on MRI outcomes in RRMS.

引用

页码：888 / 892

页数：5

共 50 条

[41] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
Darba, J.
Kaskens, L.
Sanchez-de la Rosa, R.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
[42] Quality of life in 1000 patients with relapsing-remitting multiple sclerosis and the impact of treatment initiation with intramuscular interferon beta-1a
Putzki, Norman
Hartung, Hans Peter
[J]. MULTIPLE SCLEROSIS, 2008, 14 : S149 - S149
[43] Interferon beta-1a is efficacious and well tolerated by patients with relapsing-remitting multiple sclerosis who discontinue use of interferon beta-1b
Wabant, EL
Beccariam, L
Andersson, PB
[J]. ANNALS OF NEUROLOGY, 1997, 42 (03) : T293 - T293
[44] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
Zhang, X.
Hay, J. W.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
[45] Impact of discontinuing interferon beta in patients with relapsing-remitting multiple sclerosis
Agiela, Mabroka I. M.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
[46] Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
Greenberg, Benjamin M.
Balcer, Laura
Calabresi, Peter A.
Cree, Bruce
Cross, Anne
Frohman, Teresa
Gold, Ralf
Havrdova, Eva
Hemmer, Bernhard
Kieseier, Bernd C.
Lisak, Robert
Miller, Aaron
Racke, Michael K.
Steinman, Lawrence
Stuve, Olaf
Wiendl, Heinz
Frohman, Elliot
[J]. JAMA NEUROLOGY, 2013, 70 (02) : 248 - 251
[47] Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
O'Rourke, K.
Walsh, C.
Antonelli, G.
Hutchinson, M.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (03) : 336 - 342
[48] Interferon-beta and disability progression in relapsing-remitting multiple sclerosis
Drulovic, Jelena
Kostic, Jelena
Mesaros, Sarlota
Basuroski, Irena Dujmovic
Stojsavljevic, Nebojsa
Kisic-Tepavcevic, Darija
Pekmezovic, Tatjana
[J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S65 - S69
[49] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
Cocco, Eleonora
Marrosu, Maria Giovanna
[J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
[50] The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis
Madsen, Claus
[J]. BRAIN AND BEHAVIOR, 2017, 7 (06):

← 1 2 3 4 5 →